PCSK9 levels and diabetic retinopathy: opportunities for a potential target and novel therapeutic approach in conjunction with treating dyslipidaemia.
(2024)
Journal Article
Varughese, M. S., Nayak, A. U., & Jacob, S. (in press). PCSK9 levels and diabetic retinopathy: opportunities for a potential target and novel therapeutic approach in conjunction with treating dyslipidaemia. Eye, 1-3. https://doi.org/10.1038/s41433-024-03523-1
All Outputs (4)
Idiopathic intracranial hypertension: Evolving trends of weight management with newer incretin mimetics and options for precision medicine in obesity (2024)
Journal Article
Varughese, M. S., & Nayak, A. U. (in press). Idiopathic intracranial hypertension: Evolving trends of weight management with newer incretin mimetics and options for precision medicine in obesity. Eye, https://doi.org/10.1038/s41433-024-03426-1
Letter to the Editor: PCSK9 Inhibitors and Lipid Lowering: Viewpoint on Diabetic Retinopathy (2024)
Journal Article
Varughese, M. S., & Nayak, A. U. (2024). Letter to the Editor: PCSK9 Inhibitors and Lipid Lowering: Viewpoint on Diabetic Retinopathy. OSLIRetina, 1-2. https://doi.org/10.3928/23258160-20241101-05
Fenofibrate therapy in reducing the progression of diabetic retinopathy: revisiting the FIELD and ACCORD-EYE studies through the LENS trial. (2024)
Journal Article
Varughese, M. S., Nayak, A. U., & Jacob, S. (in press). Fenofibrate therapy in reducing the progression of diabetic retinopathy: revisiting the FIELD and ACCORD-EYE studies through the LENS trial. Eye, 39, Article 15-17. https://doi.org/10.1038/s41433-024-03410-9